Drug details
Keytruda (pembrolizumab for injection)
type of PD-1PD-L1 Inhibitors
Keytruda (pembrolizumab) is a monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
This drug may have the following side effects:
- nausea,
- loss of appetite,
- itching,
- dark urine,
- rash,
- vomiting,
- diarrhea,
- shortness of breath,
- weight loss,
- chills,
- yellowing of the skin or eyes (jaundice),
- chest pain,
- dizziness,
- weight gain,
- constipation,
- muscle aches,
- wheezing,
- fainting,
- sweating,
- stomach pain (upper right side),
- increased urination,
- flushing,
- lightheadedness
- hair loss,
- feeling cold,
- shaking,
- rapid heartbeats,
- fever, and
- severe muscle weakness,
- new or worse cough,
- more frequent bowel movements than usual,
- stools that are black or tarry,
- severe stomach pain or tenderness,
- bleeding or bruising easily,
- increased thirst or hunger,
- your voice gets deeper,
- headaches that will not go away or unusual headaches,
- change in the amount or color of your urine,
- changes in your eyesight,
- severe or persistent muscle or joint pain,
- low red blood cells (anemia),
The following drugs are related to Keytruda, either as a replacement or used together:
- Adstiladrin (nadofaragene firadenovec-vncg suspension, for intravesical use)
- Rybrevant (amivantamab-vmjw for injection)
- Ayvakit (avapritinib tablets)
- Balversa (erdafitinib tablets)
- Welireg (belzutifan tablets)
- Mektovi (binimetinib tablets)
- Braftovi (encorafenib capsules)
- Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
- Tabrecta (capmatinib tablets)
- Cotellic (cobimetinib tablets)
- Cosela (trilaciclib for injection)
- Vizimpro (dacomitinib)
- Jemperli (dostarlimab-gxly injection)
- Padcev (enfortumab vedotin-ejfv for injection)
- Rozlytrek (entrectinib capsules)
- Exkivity (mobocertinib capsules)
- Zarxio (filgrastim-sndz injection)
- Fotivda (tivozanib capsules)
- Lytgobi (futibatinib tablets)
- Hepzato (melphalan for injection)
- Imjudo (tremelimumab-actl injection)
- Kimmtrak (tebentafusp-tebn injection, for intravenous use)
- Zynlonta (loncastuximab tesirine-lpyl for injection)
- Lorbrena (lorlatinib tablets)
- Lumakras (sotorasib tablets)
- Zepzelca (lurbinectedin for injection)
- Margenza (margetuximab-cmkb injection, for intravenous use)
- Portrazza (necitumumab intravenous injection)
- Opdivo (nivolumab injection)
- Odomzo (sonidegib capsules)
- Pemfexy (pemetrexed injection for intravenous use)
- Qinlock (ripretinib tablets)
- Vanflyta (quizartinib tablets)
- Retevmo (selpercatinib capsules)
- Zynyz (retifanlimab-dlwr)
- Riabni (rituximab-arrx injection)
- Truxima (rituximab-abbs injection)
- Tepmetko (tepotinib tablets)
- Tivdak (tisotumab vedotin-tftv for injection)
- Ukoniq (umbralisib tablets)